Kite, a Gilead Company, announced the primary overall survival (OS) analysis results of the phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting...
Kite’s Yescarta® CAR T-cell therapy demonstrates a statistically significant improvement in OS for initial treatment of R/R LBCL
